2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

被引：288
|
作者：
Das, Sandeep R. [1 ]
Everett, Brendan M. [2 ]
Birtcher, Kim K. [3 ]
Brown, Jenifer M. [4 ]
Januzzi, James L., Jr. [5 ]
Kalyani, Rita R. [6 ]
Kosiborod, Mikhail [7 ,8 ]
Magwire, Melissa [9 ]
Morris, Pamela B. [10 ,11 ]
Neumiller, Joshua J. [12 ,13 ]
Sperling, Laurence S. [14 ,15 ,16 ]
机构：
[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77004 USA
[4] Brigham & Womens Hosp, Cardiol, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA 02115 USA
[6] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21218 USA
[7] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[8] Univ Missouri Kansas City, Med, Kansas City, MO USA
[9] St Lukes Hlth Syst, Cardiometabol Ctr Alliance, Kansas City, MO USA
[10] Med Univ South Carolina, Seinsheimer Cardiovasc Hlth Program, Columbia, SC USA
[11] Med Univ South Carolina, Womens Heart Care, Columbia, SC USA
[12] Washington State Univ, Pullman, WA 99164 USA
[13] Washington State Univ, Pharmacotherapy, Pullman, WA 99164 USA
[14] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA
[15] Emory Univ, Atlanta, GA 30322 USA
[16] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Global Hlth, Atlanta, GA 30322 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 09期
关键词：
ACC Expert Consensus Decision Pathway; atherosclerotic cardiovascular disease; cardiovascular risk reduction; diabetes; GLP-1RA; SGLT2; inhibitor; type; 2; PEPTIDE-1 RECEPTOR AGONISTS; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; HEART-FAILURE; 2019; METHODOLOGY; GLUCOSE CONTROL; DOUBLE-BLIND; EMPAGLIFLOZIN; DISEASE; OUTCOMES;
D O I：
10.1016/j.jacc.2020.05.037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1117 / 1145
页数：29
相关论文
共 50 条
  • [1] 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Das, Sandeep R.
    Everett, Brendan M.
    Birtcher, Kim K.
    Brown, Jenifer M.
    Cefalu, William T.
    Januzzi, James L., Jr.
    Kalyani, Rita Rastogi
    Kosiborod, Mikhail
    Magwire, Melissa L.
    Morris, Pamela B.
    Sperling, Laurence S.
    Ahmad, Tariq
    Hucker, William
    Kumbhani, Dharam J.
    Marine, Joseph E.
    Piana, Robert N.
    Rao, Sunil V.
    Scherrer-Crosbie, Marielle
    Watson, Karol E.
    Wiggins, Barbara S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (24) : 3200 - 3223
  • [2] The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique
    Russo, Giuseppina
    Monami, Matteo
    Perseghin, Gianluca
    Avogaro, Angelo
    Perrone Filardi, Pasquale
    Senni, Michele
    Borghi, Claudio
    Maggioni, Aldo P.
    DIABETES THERAPY, 2021, 12 (05) : 1445 - 1461
  • [3] Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
    Schernthaner, Guntram
    Jarvis, Sarah
    Lotan, Chaim
    Prazny, Martin
    Wanner, Christoph
    Wascher, Thomas C.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 69 - 79
  • [4] Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
    Avgerinos, Ioannis
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2549 - 2557
  • [5] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [6] Empagliflozin Reduces the Risk of Mortality, Macro- and Microvascular Events in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Seufert, Jochen
    Galle, Jan-Christoph
    Manning, Martina
    Schmid, Volkmar
    Lehrke, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (04) : 294 - 306
  • [7] 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
    Chiang, Chern-En
    Ueng, Kwo-Chang
    Chao, Ting-Hsing
    Lin, Tsung-Hsien
    Wu, Yih-Jer
    Wang, Kang-Ling
    Sung, Shih-Hsien
    Yeh, Hung-, I
    Li, Yi-Heng
    Liu, Ping-Yen
    Chang, Kuan-Cheng
    Shyu, Kou-Gi
    Huang, Jin-Long
    Tsai, Cheng-Dao
    Hung, Huei-Fong
    Liu, Ming-En
    Chao, Tze-Fan
    Cheng, Shu-Meng
    Cheng, Hao-Min
    Chu, Pao-Hsien
    Yin, Wei-Hsian
    Wu, Yen-Wen
    Chen, Wen-Jone
    Lai, Wen-Ter
    Lin, Shing-Jong
    Yeh, San-Jou
    Hwang, Juey-Jen
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (07) : 587 - 621
  • [8] Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia
    Lim, Phillip
    Bleich, David
    INTERNATIONAL JOURNAL OF CARDIOLOGY CARDIOVASCULAR RISK AND PREVENTION, 2022, 14
  • [9] 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
    Lloyd-Jones, Donald M.
    Morris, Pamela B.
    Ballantyne, Christie M.
    Birtcher, Kim K.
    Daly, David D., Jr.
    DePalma, Sondra M.
    Minissian, Margo B.
    Orringer, Carl E.
    Smith, Sidney C., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (01) : 92 - 125
  • [10] Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
    Salsali, A.
    Kim, G.
    Woerle, H. J.
    Broedl, U. C.
    Hantel, S.
    DIABETES OBESITY & METABOLISM, 2016, 18 (10) : 1034 - 1040
12345